Abingworth

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs.

The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Gilead Sciences is a research-based biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to address unmet medical needs. The company's primary focus is on therapies for life-threatening infectious diseases, particularly HIV/AIDS and hepatitis B and C. Gilead's portfolio includes the hepatitis C drug Sovaldi, which emerged from its acquisition of Pharmasset, and is part of established combination treatment regimens. Additionally, Gilead is expanding its presence in oncology through strategic acquisitions, including CAR-T cell therapies such as Yescarta and Tecartus, as well as breast and bladder cancer treatments like Trodelvy. By concentrating on these critical areas, Gilead aims to enhance patient care and outcomes for those with serious health conditions.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).

Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).

Launch Therapeutics is a clinical development company that partners with biotech and biopharma firms to enhance drug development processes. The company focuses on providing expertise in regulatory, medical, and clinical operations, aiming to streamline clinical development and reduce inefficiencies. By supporting its clients in these areas, Launch Therapeutics seeks to accelerate the journey of new therapies to market.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Adaptate Biotherapeutics is a biotherapeutics company based in London, founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technology, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. The company's work holds the promise of significantly enhancing treatment options for patients, providing effective medical solutions for various immune-related conditions.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

Vera Therapeutics, a biotechnology company based in South San Francisco, California, specializes in developing innovative biologic therapeutics aimed at treating serious immunological diseases and genetic disorders. Founded in 2016 and renamed in March 2020, the company's research focuses on transformative treatments that can significantly improve patient outcomes. One of its key product candidates is atacicept, a fusion protein designed for self-administration via a weekly subcutaneous injection. Atacicept works by inhibiting both B lymphocyte stimulator and a proliferation-inducing ligand, which are involved in the production of autoantibodies that contribute to various autoimmune diseases. Additionally, Vera Therapeutics is exploring gene-editing technologies that hold the potential to address conditions such as sickle cell disease and cystic fibrosis.

Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

NuCana is a clinical-stage biopharmaceutical company dedicated to improving treatment outcomes for cancer patients through its proprietary ProTide technology. This innovative approach aims to transform commonly prescribed chemotherapy agents into safer and more effective medicines by overcoming key mechanisms of cancer resistance and enhancing the concentration of anti-cancer metabolites within tumor cells. The company is developing a portfolio of first-in-class and best-in-class pharmaceutical products, including NUC-3373, NUC-7738, and Acelarin, primarily focusing on oncology, while also maintaining the potential for broader clinical applications. With a management team experienced in the biopharmaceutical industry, NuCana is committed to addressing significant unmet medical needs in cancer treatment.

Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company utilizes a functional genomics discovery platform based on human cell lines to identify novel therapeutic targets, addressing the underlying biology of neurodegenerative diseases. By leveraging advancements in neuroscience and human genetics, Nido aims to create precise medications that restore healthy cell function and improve treatment options for conditions that significantly impact patient quality of life.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases. The company's primary focus is on its lead candidate, Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet designed for the treatment of Prader-Willi Syndrome (PWS). This product is currently undergoing evaluation in a Phase III clinical development program. Soleno Therapeutics was incorporated in 1999 and is based in Redwood City, California. The company was previously known as Capnia, Inc. before rebranding in May 2017.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered. They have assembled a team of leading scientists and ex-Big Pharma advisors with many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Virion’s mission is a developer of biological antivirals creates to offer improved therapeutics for respiratory viral infections. The company's antivirals focus on prevention and treatment of influenza and respiratory syncytial virus (RSV), enabling doctors to get a broad-spectrum therapy for respiratory viral infections, potentially simplifying and accelerating treatment by removing the need for differential diagnosis.

GTx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specializes in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders, targeting conditions such as breast cancer and Duchenne muscular dystrophy. One of its notable product candidates is enobosarm GTx-024, which is undergoing Phase II clinical trials for patients with specific types of breast cancer and postmenopausal women suffering from stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aims to advance medical solutions by leveraging new scientific approaches. In 2019, GTx was acquired by Oncternal Therapeutics in a reverse merger.

Realm Therapeutics is a biopharmaceutical company passionately committed to leveraging its proprietary technologies to protect and improve the health of adults and children. The Company's drug development focus, utilizing its immunomodulatory formulations, is targeted initially on developing small molecule therapies in inflammatory diseases with potential application in dermatology and ophthalmology, and the potential for broad applicability across a number of other diseases.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.

IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quite honestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Kesios Therapeutics Limited is a London-based company founded in 2012, focused on developing small molecule drugs for hematological malignancies, particularly multiple myeloma and related conditions. The company is dedicated to creating novel therapeutics that aim to induce normal cell death while simultaneously allowing cancer cells to survive under specific conditions, thereby addressing the unmet medical needs of patients with cancer. Through its innovative approach, Kesios seeks to advance treatment options for individuals battling these challenging diseases.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Tobira Therapeutics, Inc. is a biotechnology company focused on the research, development, and commercialization of antiviral compounds aimed at treating serious infectious diseases. Founded in 2006 and based in Princeton, New Jersey, the company specializes in the development of TBR-652 and TBR-220 antagonists, which are designed for the treatment of HIV/AIDS, hepatitis, and other related infectious conditions. Through its innovative approach, Tobira Therapeutics aims to address critical health challenges associated with these diseases.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.

Personalis, Inc. is a cancer genomics company that specializes in sequencing and data analysis services to facilitate the development of personalized cancer therapies. The company offers the NeXT Platform, which delivers critical data for therapy development, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that analyzes various human genes. Its services cater to a diverse clientele, including biopharmaceutical companies, academic institutions, non-profit organizations, diagnostics firms, and government agencies. The company focuses on advancing precision medicine and immunotherapy by providing detailed molecular insights into individual tumors and their interactions with the immune system. Founded in 2011 and headquartered in Menlo Park, California, Personalis has established partnerships to enhance its offerings and expand its impact in cancer treatment.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Paratek Pharmaceuticals is a biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing and commercializing innovative therapies targeting life-threatening diseases and public health threats for civilian and military use. Its lead products include NUZYRA (omadacycline), a broad-spectrum antibiotic available in both oral and intravenous formulations, designed for treating community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another key product is SEYSARA (sarecycline), developed for the treatment of moderate to severe acne vulgaris. Paratek's research is grounded in novel tetracycline chemistry, and the company has received Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration for its antibiotic candidates. Additionally, Paratek has established collaborative agreements with various organizations, including Tufts University and the U.S. Army Medical Research Institute of Infectious Diseases, to advance its drug development efforts.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative drug delivery solutions for patients with Type 2 diabetes. The company's primary product was the V-Go, a disposable insulin delivery device designed for continuous basal and on-demand bolus dosing, aimed at simplifying insulin management for users. Valeritas also worked on the V-Go Prefill, intended to streamline the device-filling process, and the V-Go SIM, which provided real-time tracking of insulin dosing. Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas sold its products through third-party wholesalers and medical supply distributors. However, the company filed for Chapter 11 bankruptcy on June 30, 2020, ceasing operations.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on developing innovative implantable CGM products, including the Eversense and Eversense XL systems, which measure glucose levels for up to 90 and 180 days, respectively. These systems utilize advanced fluorescence sensing technology to provide accurate and stable glucose monitoring, allowing users to manage their diabetes effectively. Senseonics primarily generates revenue from markets outside the United States, highlighting its commitment to enhancing the lives of people with diabetes through long-term, differentiated glucose management solutions.

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients.

Personalis, Inc. is a cancer genomics company that specializes in sequencing and data analysis services to facilitate the development of personalized cancer therapies. The company offers the NeXT Platform, which delivers critical data for therapy development, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that analyzes various human genes. Its services cater to a diverse clientele, including biopharmaceutical companies, academic institutions, non-profit organizations, diagnostics firms, and government agencies. The company focuses on advancing precision medicine and immunotherapy by providing detailed molecular insights into individual tumors and their interactions with the immune system. Founded in 2011 and headquartered in Menlo Park, California, Personalis has established partnerships to enhance its offerings and expand its impact in cancer treatment.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Labcyte Inc. is a laboratory instrumentation company based in San Jose, California, specializing in acoustic droplet ejection (ADE) technology for life sciences applications. Established in 2000, Labcyte develops innovative solutions for drug discovery, genomic research, cancer research, and personalized medicine through its precise liquid dispensing technology. This technology utilizes focused acoustic energy to eject nanoliter-scale droplets of fluid, allowing for high accuracy and reduced consumption of materials. Labcyte's product offerings include automation systems, laboratory workstations, and control software aimed at enhancing research efficiency and data reliability. The company operates as a subsidiary of Beckman Coulter, Inc. and maintains additional offices across multiple countries, including Canada, the United Kingdom, and Japan.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.

Sonitus Medical Inc. is a privately held medical device company based in San Mateo, California, focused on delivering innovative hearing solutions for patients with hearing difficulties. The company is recognized as an emerging leader in bone conduction hearing devices, particularly through its flagship product, the SoundBite Hearing System. This system is notable for being the world's first non-invasive and removable hearing solution, which transmits sound through the teeth, leveraging the principle of bone conduction. The device is FDA cleared as a prosthetic option for treating single-sided deafness and conductive hearing loss. Sonitus Medical aims to expand its technology for future applications, including mixed hearing loss and tinnitus, along with potential consumer and covert communication uses. Founded in June 2006, the company collaborates with otologists, ENTs, and audiologists to enhance the auditory experience for patients.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.

Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative drug delivery solutions for patients with Type 2 diabetes. The company's primary product was the V-Go, a disposable insulin delivery device designed for continuous basal and on-demand bolus dosing, aimed at simplifying insulin management for users. Valeritas also worked on the V-Go Prefill, intended to streamline the device-filling process, and the V-Go SIM, which provided real-time tracking of insulin dosing. Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas sold its products through third-party wholesalers and medical supply distributors. However, the company filed for Chapter 11 bankruptcy on June 30, 2020, ceasing operations.

Personalis, Inc. is a cancer genomics company that specializes in sequencing and data analysis services to facilitate the development of personalized cancer therapies. The company offers the NeXT Platform, which delivers critical data for therapy development, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that analyzes various human genes. Its services cater to a diverse clientele, including biopharmaceutical companies, academic institutions, non-profit organizations, diagnostics firms, and government agencies. The company focuses on advancing precision medicine and immunotherapy by providing detailed molecular insights into individual tumors and their interactions with the immune system. Founded in 2011 and headquartered in Menlo Park, California, Personalis has established partnerships to enhance its offerings and expand its impact in cancer treatment.

MD On-Line Inc. is a leading provider of electronic data interchange (EDI) solutions that facilitate the critical connection between doctors and payers. Its offerings enable electronic data capture and entry, and claim and transactional data submission to payers. Co-branded and endorsed by more than 30 major insurers and increasing its presence in providers' offices of all sizes, MD On-Line is transacting the business of healthcare, helping to make the healthcare system significantly more cost-effective by eradicating inefficiencies. In addition to claims processing, MD On-Line offers real-time services for eligibility verification, referrals, claim status inquiries, and electronic remittance advice (ERAs). Its "all-payer" EDI solutions encompass a network of more than 2,000 payer organizations and are used by more than 45,000 healthcare providers nationwide.

Lombard Medical, Inc. is a medical technology company that specializes in developing, manufacturing, and marketing endovascular stent-grafts for the repair of aortic aneurysms. Its principal product, Aorfix, is designed to treat abdominal aortic aneurysms (AAAs) in patients with neck angulations of up to 90 degrees. The company's product portfolio also includes the Altura endovascular stent-graft system for standard AAA anatomies, and advanced delivery systems like Aorflex and IntelliFlex LP, which enhance the precision of stent-graft deployment. Lombard Medical markets its products through a direct sales force and distributors, primarily targeting state- or government-owned hospitals. Established in 2000 and headquartered in Didcot, the United Kingdom, Lombard Medical serves various international markets, with a significant portion of its revenue derived from Japan.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

IS Pharma plc, through its subsidiaries, develops, acquires, and commercializes various pharmaceutical and medical devices focusing on the areas of critical care, oncology, and neurology in the United Kingdom and internationally. The company's commercial product line includes Volplex, a sterile, apyrogenic plasma substitute solution for intravenous infusion; Cryogesic and Dermogesic, vapo-coolant sprays for topical local analgesia prior to minor invasive procedures; Mysoline, an oral treatment for various forms of epilepsy and essential tremor; Aloxi, an antagonist used for the prevention of nausea and vomiting; and Isoplex, a succinylated gelatin plasma substitute in a balanced electrolyte solution providing fluid volume replacement and improvement in electrolyte balance. Its late stage development products comprise Haemopressin, an injectable product for treatment of bleeding oesophageal varices; Acoranil, a liquid presentation of antidepressant for patients unable to take tablets; AquiHex, a solution to help reduce hospital acquired infections; and Gentispray, an ear spray combination of an antibiotic and steroid for the treatment of otitis externa. The company's partnered product line consists of OptiFlo, various catheter irrigation solutions, distributed by Bard Ltd.; ContiSol, a brand of catheter irrigation solutions; and Micelle Nanotechnology, a drug delivery system in development, which is licensed to Plethora Solutions Holdings PLC for the treatment of interstitial cystitis. IS Pharma plc was formerly known as Maelor plc and changed its name to IS Pharma plc in April 2008. The company is based in Chester, the United Kingdom.

Pathwork Diagnostics, located in Redwood City, California, specializes in developing and delivering innovative molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers, by utilizing genomic information from the tumors. Pathwork Diagnostics offers laboratory services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen tissues, providing essential support in cancer diagnosis and treatment planning.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing therapies aimed at improving the lives of patients with rare diseases, particularly those affecting the central nervous system. The company’s lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome, as well as Phase II trials for other rare epileptic conditions. Additionally, Zogenix is developing MT1621, a therapy for mitochondrial DNA depletion disorder, and is collaborating with Tevard Biosciences to advance gene therapies for Dravet syndrome and other genetic epilepsies. Founded in 2006 and headquartered in Emeryville, California, Zogenix aims to address significant unmet medical needs in the field of neurology and pain management through innovative treatment options.

Avila Therapeutics is focused on designing and developing covalent drugs aimed at treating viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule that acts as a protease inhibitor for hepatitis C virus. Founded in 2006 and based in Waltham, Massachusetts, Avila Therapeutics operates as a subsidiary of Celgene Corporation, following its acquisition in 2012. The company has also established a strategic alliance with Sanofi-Aventis to enhance its research and development efforts.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

Amarin Corporation is a clinical-stage biopharmaceutical company dedicated to enhancing the treatment of cardiovascular disease. The company is actively developing its lead candidate, AMR101, which is undergoing pivotal Phase 3 trials to assess its effectiveness in lowering triglyceride levels in patients with very high triglycerides and those with mixed dyslipidemia who are on statin therapy. Amarin leverages its expertise in lipid science and the therapeutic potential of polyunsaturated fatty acids to address cardiovascular health. The company is headquartered in Dublin, Ireland, with research and development operations based in Mystic, Connecticut, USA. Its commitment to improving cardiovascular health positions it to meet the needs of millions of patients worldwide.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing therapies aimed at improving the lives of patients with rare diseases, particularly those affecting the central nervous system. The company’s lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome, as well as Phase II trials for other rare epileptic conditions. Additionally, Zogenix is developing MT1621, a therapy for mitochondrial DNA depletion disorder, and is collaborating with Tevard Biosciences to advance gene therapies for Dravet syndrome and other genetic epilepsies. Founded in 2006 and headquartered in Emeryville, California, Zogenix aims to address significant unmet medical needs in the field of neurology and pain management through innovative treatment options.

Intellikine is engaged in the discovery and development of small molecule therapies that specifically target the PI3K/Akt/mTOR signaling pathway. The company focuses on creating innovative drug candidates aimed at treating various conditions, including cancer, inflammation, and autoimmune disorders. Its product lineup features INK128, an orally available TORC1/2 inhibitor designed for solid tumor malignancies, and INK1197, a dual PI3K selective inhibitor intended for patients suffering from immune-mediated inflammatory diseases like rheumatoid arthritis and asthma. Intellikine is dedicated to assembling a talented team and an effective discovery platform to accelerate the development of next-generation medical breakthroughs in kinase inhibitor therapies.

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the clinical development and registration of pharmaceutical products, primarily in Japan. Established in 2008 and headquartered in Pleasanton, California, the company aims to expedite the introduction of new drugs to major markets by providing financial support and strategic development expertise to its pharmaceutical and biotechnology partners. In response to the challenges faced by these industries, such as reduced research and development budgets and limited external funding, SFJ Pharmaceuticals assumes the clinical and regulatory risks associated with drug development. The company's platform facilitates late-stage trial design, execution, and regulatory processes, allowing clinical professionals to advance drug candidates across various therapeutic areas efficiently.

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products to address unmet medical needs in the fields of psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through partnerships with major pharmaceutical companies. Two of these compounds are existing marketed drugs that are undergoing testing for new indications, aiming to expand their applications to treat neurological and psychiatric conditions such as anxiety and Parkinson's disease. In addition to its product development efforts, Synosia Therapeutics also offers clinical development programs and research services.